Converti edgeX EDGEX in Transfidelity FIDEL

EdgeX è un exchange di futures perpetui decentralizzato che combina la velocità e le prestazioni degli exchange centralizzati con la trasparenza e l'autocustodia della finanza decentralizzata (DeFi). La piattaforma dispone di un motore di corrispondenza degli ordini fuori dalla blockchain con liquidazione onchain, consentendo un trading ad alta velocità e bassa latenza su un'ampia gamma di criptoasset. A causa di una sovrapposizione di ticker, Coinbase utilizzerà il ticker "EDGEX" per questo asset anziché la sua designazione on-chain o nel white paper di MiCA "EDGE". Questa modifica garantisce compatibilità con gli asset esistenti sulla nostra piattaforma ed evita potenziali conflitti. La modifica non influisce sulla funzionalità o sul valore dell'asset sottostante.

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.